Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The World Hip Trauma Evaluation Four (WHiTE Four) study has now opened for recruitment in its first two sites (Northumbria Specialist Emergency Care Hospital in Northumberland, and John Radcliffe Hospital in Oxford). The study is a multi-centre, multi-surgeon, parallel, two arm, randomised controlled trial that will be running in 8+ hospitals in the UK. It is embedded within the WHiTE Comprehensive Cohort Study. The study includes a two-way superiority comparison between the X-Bolt Hip System (XHS) and Sliding Hip Screw fixations, and patients who present to A&E with a trochanteric fracture of the hip, who are 60 years of age and older, are eligible to participate. The trial will last a total of 38 months, with participant recruitment taking 18 months and final follow-up at 12 months post-surgery. Based upon 2013 data in the National Hip Fracture Database, the involved units perform approximately 800 of such procedures per year. The trial’s primary outcome is to quantify and draw inferences on observed differences in participants’ health status between the trial treatment groups at 4 months post-injury, and the secondary outcomes are to quantify and draw inferences on observed differences in the risk of all cause revision surgery, and  in the proportion of complications/radiographic changes within the first year post-injury between the trial treatment groups. 

For more information please visit 

Similar stories

WHiTE Four trial results!


The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!


The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!


The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand


Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!


The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.